<DOC>
	<DOCNO>NCT01674270</DOCNO>
	<brief_summary>To assess effect neo-adjuvant GnRH antagonist , degarelix , versus LHRH agonist intratumoral level androgen .</brief_summary>
	<brief_title>Degarelix Neo-Adjuvant Radical Prostatectomy Trial</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Men &gt; 18 = &lt; 75 year age Willing able provide inform consent , either alone aid translator Histologically confirm prostate cancer determine transrectal ultrasound ( TRUS ) guide prostate biopsy perform within 6 month study enrolment Gleason Score &gt; = 7and/or prostate cancer clinical stage T2 disease . Candidates open radical prostatectomy consider surgically resectable urologic evaluation Normal organ marrow function define follow criterion : Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Previous current use hormonal management prostate cancer ( surgical castration hormonal manipulation , include GnRH receptor agonist , GnRH receptor antagonist , antiandrogens , estrogen , megestrol acetate , ketoconazole ) History receive radiation pelvic area . Previously receive therapy 5alpha reductase inhibitor finasteride and/or dutasteride 4 week prior randomization . History bilateral orchiectomy , adrenalectomy , hypophysectomy . History severe untreated asthma , anaphylactic reaction , severe urticaria and/or angioedema . Known hypersensitivity towards component investigational medicinal product Casodex ( bicalutamide ) excipients . Marked baseline prolongation QT/QTcF interval ( e.g . repeat demonstration QTcF interval &gt; 450 m ) . History risk factor Torsade de Pointes ventricular arrhythmia ( e.g . heart failure , hypokalemia , family history Long QT Syndrome ) . Previous history presence another malignancy , prostate cancer treat squamous / basal cell carcinoma skin , within last five year . Clinically significant laboratory abnormality ( e.g . severe renal hepatic impairment ) judgment Investigator would affect patient 's health outcome trial . Clinically significant disorder ( prostate cancer ) include , limited , renal , haematological , gastrointestinal , endocrine , cardiac , neurological , psychiatric disease , alcohol drug abuse condition , may affect patient 's health outcome trial judge Investigator . Use natural medicine think endocrine effect prostate cancer ( e.g . saw palmetto St. John 's Wort ) 4 week prior randomization . Mental incapacity language barrier preclude adequate understanding co operation . Use investigational drug within last 28 day precede Screening Visit longer consider possibly influence outcome current trial . Previously participate degarelix trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>